News

Dr. Khanani highlights data from MERLIN showing noninferiority of brolucizumab to aflibercept in nAMD treatment, but a higher rate of intraocular inflammation.

Treatment with statins, nitrates, dihydropyridines, verapamil, and proton-pump inhibitors were predictors of death or ischemic events for patients in the HGFR group.

Dr. Sheth discusses the data from the late-breaking Phase 2B ALTISSIMO study.

The least selected attributes were food and medication restrictions and A1c lowering followed by risk of diabetic ketoacidosis, risk of genital infection, and the avoidance of severe hypoglycemia.

Dr. Elewski hopes that in the future more clinicians will prescribe biologics such as secukinumab and etancercept for the treatment of psoriasis.

Though not all hemangioma last past 10 years old in pediatric patients, some untreated hemangioma are associated with high risk of ulceration.

Ropeginterferon Alfa-2b-NJFT (Besremi) is approved by the FDA for the treatment of polycythemia vera regardless of a patient's treatment history.

Certain biologics such as infliximab have aided psoriasis patients in the mitigation of symptoms from the COVID-19 virus.

Dr. Swanson also details the effects of the COVID-19 pandemic on her practice with the implementation of telemedicine.

Dr. Elewski speaks of the safety and efficacy of several new and developing therapies, including bimekizumab treatment which has yet to be approved in the United States.

Swanson noted the efficacy and safety of dupilumab, which she feels revolutionized patient care.

Dr. Khattri speaks of the benefits of diagnosing the condition early in psoriasis patients, as well as what dermatologists can do before referring a patient to a rheumatologist.

New therapies are breaking ground in the world of vitiligo research, which Dr. Desai believes will result in FDA approvals in the coming years.

Dr. Regillo discusses the efficacy and durability of faricimab for wet AMD treatment in TENAYA and LUCERNE, showing noninferiority to aflibercept.

Dr. Singh discusses the aging population in ophthalmology care, advances including port delivery systems, and the potential rapid uptake of faricimab in treatment.

A geographical study shows patients in areas with lower income, education, and higher rates of ophthalmic disease may be a greater distance from a trial site.

Dr. Singh discusses results from TENAYA and LUCERNE on faricimab compared to afilbercept in patients with nAMD.

The COLUMBUS-AMD trial suggests the investigative biosimilar could benefit patients newly diagnosed with nAMD.

A cost-based assessment of Protocol W and PANORAMA clinical data suggests diabetic retinopathy may be less costly to prevent than macular edema.

Deepak Bhatt, MD, MPH, discusses the results of a pooled analysis of the SOLOIST and SCORED trials assessing effects of sotagliflozin based on baseline eGFR among patients included in the trials.

Dr. Sternberg discusses step therapy in wetAMD treatment and his opinions in favor of its use.

Bevacizumab-vikg was associated with statistically significant improvements in patient BCVA scores over a period of 12 months, according to phase 3 findings.

A meta-analysis comparison of dosing regimens for patients with nAMD show little difference in efficacy, but differences in patient involvement in care.

A phase 1 trial of the investigative drug suggests its promise in a novel strategy of managing patients with retinal fluid.

Dr. Lally discusses the effect of avacincaptad pegol treatment on the progression of geographic atrophy and intermediate age-related macular degeneration.

Findings from the phase 2 INFINITY suggest a more dose-dependent influence on safety outcomes in patients receiving sustained benefit for diabetic macular edema.

An update from the PIONEER trial shows the combination gene therapy and medical device strategy is safe and tolerable, while providing cases of improved light perception.

Dr. Haller discusses issues in diversity and inclusion in retina, but provides avenues for solutions and what needs to come next.